Cortexin in plain English — the bovine brain extract used in stroke recovery
8 min read · Uplevel editorial
You survive the stroke. That part goes as well as it can — the clot is caught early, the emergency intervention works, you're alive and you go home. What no one prepares you for is the months afterward. The word that used to come in half a second now takes four. You lose the thread of a sentence mid-paragraph. You read the same line three times and it doesn't stay. The neurologist says you should be seeing improvement, that the brain is plastic, that recovery takes time — and all of that is true, and none of it tells you what to do about the fact that your thinking feels like it's running through wet concrete.
In a Russian neurology ward, the next step would likely include Cortexin. In an American neurology ward, the word has never been spoken.
Cortexin is a preparation of low-molecular-weight polypeptides extracted from the cerebral cortex of young cattle. The extraction process isolates peptide fractions with molecular weights below 10,000 daltons — small enough to potentially cross biological barriers, small enough to act on cellular signaling machinery, and complex enough that the preparation contains multiple distinct peptides rather than a single defined compound. It was developed in Russia in the 1980s and has been in clinical use there, and across the CIS countries, ever since. In Russia, it is an approved pharmaceutical. It is not approved by the FDA and is not part of standard medical practice in the United States.
The extraction approach follows the logic of the Khavinson bioregulator tradition: the cerebral cortex contains short peptide regulators of cortical function, and a preparation enriched in those peptides can, when administered, provide informational signals that support cortical homeostasis. What that means in practice is that Cortexin doesn't work through a single target the way a receptor agonist or enzyme inhibitor would. It works pleiotropically — through multiple mechanisms simultaneously — in ways that are consistent with its mixed peptide composition.
Several mechanisms have been studied. Cortexin appears to upregulate the expression of neurotrophic factors — including nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) — which support neuronal survival, synaptic plasticity, and the repair processes that follow ischemic injury. In the context of stroke, this matters because ischemia triggers a cascade of cellular damage that extends beyond the initial infarct zone; the penumbral tissue around the core injury is metabolically stressed and vulnerable to secondary damage. Neurotrophic support in that window is a pharmacological strategy for preserving tissue that might otherwise be lost.
Cortexin also shows antioxidant activity in preclinical work — reducing markers of oxidative stress in neural tissue after experimental ischemia. Oxidative stress is a major driver of secondary neuronal death in the hours and days following stroke, so the antioxidant profile is pharmacologically relevant rather than incidental. Additionally, research has examined Cortexin's effects on the balance between excitatory and inhibitory neurotransmission — specifically its apparent modulation of glutamate and GABA activity. Excitotoxicity, the death of neurons driven by excessive glutamate signaling after ischemia, is one of the central mechanisms of post-stroke damage, and compounds that can modulate this balance without suppressing neurological function are actively sought in stroke pharmacology.
The anti-inflammatory signaling effects add another layer. Neuroinflammation following stroke is now understood to be both protective and damaging depending on its timing and character, and several studies have examined Cortexin's effects on inflammatory markers in both preclinical models and clinical populations.
The route of administration is intramuscular injection. Cortexin is typically used in treatment courses of 10 milligrams per day injected IM for ten consecutive days, with courses repeated at intervals — the exact protocol varying by clinical indication and physician judgment. This is not a compound you take as a capsule or nasal spray. The injection route reflects both the peptide nature of the compound — which would be degraded significantly by oral administration — and the clinical tradition in Russia, where injection-based peptide therapies are more normalized than in the Western outpatient context.
The clinical evidence for Cortexin in stroke recovery comes substantially from the Russian neurological literature. Studies have examined outcomes including scores on neurological status scales, cognitive function batteries, and functional recovery measures in patients treated with Cortexin versus standard care alone. The reported results are generally favorable — improvements in neurological deficit scores, better cognitive outcomes, and functional markers — though the study designs vary in quality and most would not meet FDA's methodological standards for statistical rigor and blinding. The evidence base is real and extensive by volume; it is limited by Western evidentiary standards. That distinction matters and is worth holding honestly.
Beyond stroke, Cortexin has been studied and used clinically in Russia for traumatic brain injury — where the neurotrophic and neuroprotective mechanisms are similarly relevant — for vascular cognitive impairment, which describes the cognitive decline associated with chronic cerebrovascular disease rather than a single acute event, and for pediatric neurodevelopmental conditions including perinatal hypoxia, delayed development, and conditions on the cerebral palsy and attention-deficit spectrum. The pediatric use has generated its own literature, with studies examining outcomes in children with perinatal brain injury and developmental delays. This is a significant part of the Russian Cortexin clinical record.
More recently, there has been interest in Cortexin for post-COVID neurological effects — the cognitive dysfunction, fatigue, and attention problems that persist in a subset of people after SARS-CoV-2 infection. The mechanisms that make Cortexin potentially relevant to stroke recovery — neurotrophic support, anti-inflammatory signaling, BDNF upregulation — are similarly plausible rationales for post-infectious neuroinflammatory conditions. Russian clinical groups have published early observations in this context, though the evidence here is even more preliminary than the stroke literature.
It is worth being explicit about what the compound is and what it isn't. Cortexin is not a drug synthesized from a known active molecule with a defined mechanism at a specific receptor. It is a complex biological preparation — more like a peptide-rich tissue extract than a pharmaceutical compound in the Western sense. This means its composition varies to some extent between batches; characterization of the exact peptide mixture is more difficult than characterization of a single defined compound; and the mechanism of action, while plausible and partially characterized, is not as precisely mapped as it would be for a modern pharmaceutical target.
The safety profile, built across decades and large numbers of patients in Russian clinical use, appears favorable. Serious adverse events are uncommon in the literature. The most common issues are local injection site reactions and occasional mild headache. There are no widely reported serious systemic toxicities in the clinical record. This matters — a long safety record in clinical use is informative even when it doesn't substitute for Western regulatory review.
For anyone interested in Cortexin outside Russia, the practical situation is straightforward: it is not FDA-approved, it cannot be prescribed by an American physician as a licensed pharmaceutical, and accessing it requires navigating channels outside the standard pharmacy system. Discussing it with a prescribing provider who is knowledgeable about the evidence base is the appropriate starting point, with eyes open about the evidentiary limitations and the regulatory status.
What the Cortexin story ultimately illustrates is that the treatment of neurological injury has a wider horizon than standard Western neurology recognizes. Post-stroke cognitive recovery, traumatic brain injury, vascular cognitive impairment — these are conditions with enormous unmet need in Western medicine, where the approved pharmacological options are thin. A compound with decades of clinical use and a mechanistically coherent rationale for neurological benefit deserves serious attention even when it comes wrapped in the limitations of non-Western evidentiary standards. Not credulous attention — serious attention, with appropriate awareness of what the evidence does and doesn't establish. That's a different posture than either dismissal or uncritical enthusiasm, and it's the only one that does the subject justice.
Frequently asked